Evidence map›Paper›PMID 25749829›Full record

ArticleHaematologica2015

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.

Elodie Bohers, Pierre Julien Viailly, Sydney Dubois, Philippe Bertrand, Catherine Maingonnat, Sylvain Mareschal, Philippe Ruminy, Jean-Michel Picquenot, Christian Bastard, Fabienne Desmots and 4 more

2 registry-linked trialsOpen access · goldAbstract readLetter
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07060001 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia

TypeinterventionalSponsorThe Methodist Hospital Research InstituteRan2026 to 2029Enrolled112ConditionsAcute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)Arms5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C)
NCT07652580 recruitingnot on this mapstarted 2025, after this paper: background citation

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System

TypeobservationalSponsorHenry M. Jackson Foundation for the Advancement of Military MedicineRan2025 to 2028Enrolled300ConditionsNon-Hodgkin Lymphoma, Lymphoma Non-Hodgkin, B-cell Lymphoma, Immune Dysregulation
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Cell-Free DNA for the Management of Classical Hodgkin Lymphoma.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. Genomics of aggressive B-cell lymphoma.Hematology. American Society of Hematology. Education Program · 2018
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Elodie BohersINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Pierre Julien ViaillyINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Sydney DuboisINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Philippe BertrandINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Catherine MaingonnatINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Sylvain MareschalINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Philippe RuminyINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Jean-Michel PicquenotDepartment of Pathology, Centre Henri Becquerel, Rouen, France.
Christian BastardINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France.
Fabienne DesmotsUMR INSERM U917, CHU Pontchaillou, Rennes, France.
Thierry FestUMR INSERM U917, CHU Pontchaillou, Rennes, France.
Karen LeroyINSERM U955, Henri Mondor Hospital, Creteil, France.
Hervé TillyINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France.
Fabrice JardinINSERM U918, Centre Henri Becquerel, Université de Rouen, IRIB, France Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France fabrice.jardin@chb.unicancer.fr.
Inserm · FRBiotherapy of Genetic Diseases, Inflammatory Disorders and Cancers · FRCentre Henri Becquerel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overB-LymphocytesCell Transformation, NeoplasticDNA, NeoplasmFemaleGerminal CenterHigh-Throughput Nucleotide SequencingHumansLymphocyte ActivationLymphomaLymphoma, Large B-Cell, DiffuseMaleDNA, NeoplasmNeoplasm Proteinsdiffuse large B-cell lymphomaliquid biopsymutationsNGS

Identifiers

PMID25749829
PMCPMC4486242
OpenAlexW2123872027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.